| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $398,442 ) |
| | 2025 | 2025 | MOUNTAINPASS TECHNOLOGY LLC | 2 WISCONSIN CIR | CHEVY CHASE | MD | 20815-7007 | MONTGOMERY | USA | R42DA062250 | MyTrials: An Integrated Tool to Support Remote Biomarker Capture within Decentralized Clinical Trials for Substance Use Disorders | 000 | 1 | NIH | 4/4/2025 | $400,000 |
| | 2025 | 2022 | MOUNTAINPASS TECHNOLOGY LLC | 2 WISCONSIN CIR | CHEVY CHASE | MD | 20815-7007 | MONTGOMERY | USA | R41TR004224 | Development and Evaluation of an Integrated Biomarker Capture System for Use in Remote Trials | 000 | 1 | NIH | 5/13/2025 | -$1,558 |
|
| Issue Date FY: 2024 ( Subtotal = -$15,323 ) |
| | 2024 | 2022 | MOUNTAINPASS TECHNOLOGY LLC | 2 WISCONSIN CIR | CHEVY CHASE | MD | 20815-7007 | MONTGOMERY | USA | R42MH108219 | Development and testing of a behavioral activation mobile therapy for elevated depressive symptoms | 000 | 4 | NIH | 2/9/2024 | $0 |
| | 2024 | 2022 | MOUNTAINPASS TECHNOLOGY LLC | 2 WISCONSIN CIR | CHEVY CHASE | MD | 20815-7007 | MONTGOMERY | USA | R41TR004224 | Development and Evaluation of an Integrated Biomarker Capture System for Use in Remote Trials | 000 | 1 | NIH | 5/9/2024 | $0 |
| | 2024 | 2021 | MOUNTAINPASS TECHNOLOGY LLC | 2 WISCONSIN CIR | CHEVY CHASE | MD | 20815-7007 | MONTGOMERY | USA | R41DA053856 | Development and Evaluation of a Brief Behavioral Activation Mobile Application for Nicotine Vaping Cessation Among Adolescent Primary Care Patients | 000 | 1 | NIH | 9/4/2024 | -$15,323 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | MOUNTAINPASS TECHNOLOGY LLC | 2 WISCONSIN CIR | CHEVY CHASE | MD | 20815-7007 | MONTGOMERY | USA | R41DA053856 | Development and Evaluation of a Brief Behavioral Activation Mobile Application for Nicotine Vaping Cessation Among Adolescent Primary Care Patients | 000 | 1 | NIH | 5/17/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,056,704 ) |
| | 2022 | 2022 | MOUNTAINPASS TECHNOLOGY LLC | 2 WISCONSIN CIR STE 700 | CHEVY CHASE | MD | 20815-7007 | MONTGOMERY | USA | R42MH108219 | Development and testing of a behavioral activation mobile therapy for elevated depressive symptoms | 000 | 4 | NIH | 2/11/2022 | $732,620 |
| | 2022 | 2022 | MOUNTAINPASS TECHNOLOGY LLC | 2 WISCONSIN CIR STE 700 | CHEVY CHASE | MD | 20815-7007 | MONTGOMERY | USA | R41TR004224 | Development and Evaluation of an Integrated Biomarker Capture System for Use in Remote Trials | 000 | 1 | NIH | 4/27/2022 | $324,084 |
|
| Issue Date FY: 2021 ( Subtotal = $1,059,540 ) |
| | 2021 | 2021 | MOUNTAINPASS TECHNOLOGY LLC | 2 WISCONSIN CIR STE 700 | CHEVY CHASE | MD | 20815-7007 | MONTGOMERY | USA | R42MH108219 | Development and testing of a behavioral activation mobile therapy for elevated depressive symptoms | 000 | 3 | NIH | 2/4/2021 | $739,540 |
| | 2021 | 2021 | MOUNTAINPASS TECHNOLOGY LLC | 2 WISCONSIN CIR STE 700 | CHEVY CHASE | MD | 20815-7007 | MONTGOMERY | USA | R41DA053856 | Development and Evaluation of a Brief Behavioral Activation Mobile Application for Nicotine Vaping Cessation Among Adolescent Primary Care Patients | 000 | 1 | NIH | 4/23/2021 | $320,000 |
|
| Issue Date FY: 2020 ( Subtotal = $749,671 ) |
| | 2020 | 2020 | MOUNTAINPASS TECHNOLOGY LLC | 2 WISCONSIN CIR STE 700 | CHEVY CHASE | MD | 20815-7007 | MONTGOMERY | USA | R42MH108219 | Development and testing of a behavioral activation mobile therapy for elevated depressive symptoms | 000 | 2 | NIH | 2/28/2020 | $749,671 |
|
| Issue Date FY: 2019 ( Subtotal = -$3,729 ) |
| | 2019 | 2016 | MOUNTAINPASS TECHNOLOGY LLC | 2 WISCONSIN CIR STE 700 | CHEVY CHASE | MD | 20815-7007 | MONTGOMERY | USA | R41MD010491 | Development of a Behavioral Activation Mobile App for depressed Latinos | 000 | 1 | NIH | 1/16/2019 | $0 |
| | 2019 | 2015 | MOUNTAINPASS TECHNOLOGY LLC | 2 WISCONSIN CIR STE 700 | CHEVY CHASE | MD | 20815-7007 | MONTGOMERY | USA | R41MH108219 | Development and testing of a behavioral activation mobile therapy for elevated depressive symptoms | 000 | 1 | NIH | 1/9/2019 | -$3,729 |
|
| Issue Date FY: 2017 ( Subtotal = $0 ) |
| | 2017 | 2015 | MOUNTAINPASS TECHNOLOGY LLC | 2 WISCONSIN CIR STE 700 | CHEVY CHASE | MD | 20815-7007 | MONTGOMERY | USA | R41MH108219 | Development and testing of a behavioral activation mobile therapy for elevated depressive symptoms | 000 | 1 | NIH | 9/5/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $224,977 ) |
| | 2016 | 2016 | MOUNTAINPASS TECHNOLOGY LLC | 2 WISCONSIN CIR STE 700 | CHEVY CHASE | MD | 20815 | MONTGOMERY | USA | R41MD010491 | Development of a Behavioral Activation Mobile App for depressed Latinos | 000 | 1 | NIH | 9/1/2016 | $224,977 |
|
| Issue Date FY: 2015 ( Subtotal = $224,573 ) |
| | 2015 | 2015 | MOUNTAINPASS TECHNOLOGY LLC | 2 WISCONSIN CIR STE 700 | CHEVY CHASE | MD | 20815 | MONTGOMERY | USA | R41MH108219 | Development and testing of a behavioral activation mobile therapy for elevated depressive symptoms | 000 | 1 | NIH | 8/31/2015 | $224,573 |
|
|
